作者
Laure Elens, Rachida Bouamar, Dennis A Hesselink, Vincent Haufroid, Ilse P van der Heiden, Teun van Gelder, Ron HN van Schaik
发表日期
2011/11/1
期刊
Clinical chemistry
卷号
57
期号
11
页码范围
1574-1583
出版商
Oxford University Press
简介
BACKGROUND
Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. Tac pharmacokinetics varies between individuals and thus complicates its use in preventing rejection after kidney transplantation. This variability might be caused by genetic polymorphisms in metabolizing enzymes.
METHODS
We used TaqMan analyses to evaluate the impact of a newly discovered CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) single-nucleotide polymorphism (SNP) (rs35599367C>T; CYP3A4*22) on Tac pharmacokinetics in 185 renal transplant recipients who participated in an international randomized controlled clinical trial (fixed-dose, concentration-controlled study).
RESULTS
The overall mean daily-dose requirement to reach the same predose Tac blood concentration was 33% lower for carriers of the T variant allele than for …
学术搜索中的文章
L Elens, R Bouamar, DA Hesselink, V Haufroid… - Clinical chemistry, 2011